Turning Point Therapeutics

General Information


We are a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Our internally developed and wholly owned pipeline of next-generation tyrosine kinase inhibitors (TKIs) targets numerous genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. The pervasive challenges of intrinsic and acquired treatment resistance often limit the response rate and durability of existing therapies.

Employees: 50
Founded: 2013
Contact Information
Address 10628 Science Center Drive, Ste. 225, San Diego, CA 92121, US
Phone Number (858) 926-5251
Web Address http://www.tptherapeutics.com
View Prospectus: Turning Point Therapeutics
Financial Information
Market Cap $533.8mil
Revenues $0 mil (last 12 months)
Net Income $-24.8 mil (last 12 months)
IPO Profile
Symbol TPTX
Exchange NASDAQ
Shares (millions): 9.3
Price range $18.00 - $18.00
Est. $ Volume $166.5 mil
Manager / Joint Managers Goldman Sachs/ SVB Leerink/ Wells Fargo Securities
CO-Managers Canaccord Genuity
Expected To Trade: 4/17/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change